Analysis on whether long-term medication must be adhered to after taking Ixazomib (Enleri)

Ixazomib (Ixazomib) is an oral proteasome inhibitor mainly used to treat multiple myeloma (MM). Its mechanism of action is to induce myeloma cell apoptosis by inhibiting proteasome activity and preventing cancer cells from degrading abnormal proteins. Because multiple myeloma is a chronic, relapsing disease, ixazomib is often used as maintenance therapy or as part of a combination regimen to extend progression-free survival (PFS) and reduce the risk of relapse.

In clinical practice, whether ixazomib needs to be taken long-term depends on the patient's disease status, treatment response and tolerance. For treatment-naïve patients or patients who have achieved remission after induction therapy, doctors may recommend continuing oral ixazomib for maintenance therapy to consolidate the efficacy and delay disease recurrence. Usually maintenance treatment can last from several months to several years, but the efficacy and side effects need to be evaluated regularly.

Long-term use of ixazomib requires attention to potential adverse reactions, including hematological toxicity (such as neutropenia, thrombocytopenia), gastrointestinal reactions, and peripheral neuropathy. Patients need to regularly review their blood count, liver and kidney function, and nervous system conditions while taking the medication, and adjust the dosage or take medication intermittently according to tolerance under the guidance of a doctor to ensure the safety and sustainability of the treatment.

In general, ixazomib does not have to be taken indefinitely for all patients, but the treatment period is determined based on individualized treatment plans and clinical assessment. Long-term medication is usually suitable for patients with stable disease and good tolerance to prolong the efficacy and reduce the risk of recurrence; in the case of significant adverse reactions or complete disease remission, doctors may consider adjusting or temporarily discontinuing the medication to ensure that the treatment strikes a balance between safety and efficacy.

Reference link:https://www.drugs.com